Loading...

BioXcel Therapeutics

DB:BX2
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BX2
DB
$152M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • BioXcel Therapeutics has significant price volatility in the past 3 months.
BX2 Share Price and Events
7 Day Returns
-6.2%
DB:BX2
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
13.9%
DB:BX2
-9.2%
DE Biotechs
-6.7%
DE Market
BX2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioXcel Therapeutics (BX2) -6.2% -6.4% - 13.9% - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • BX2 outperformed the Biotechs industry which returned -9.2% over the past year.
  • BX2 outperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is BioXcel Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BioXcel Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BioXcel Therapeutics.

DB:BX2 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:BX2
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:BX2 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BioXcel Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:BX2 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.01%)
2019 -42.30 Analyst x1 -39.16
2020 -84.70 Analyst x1 -72.60
2021 -91.10 Analyst x1 -72.30
2022 72.60 Analyst x1 53.35
2023 485.40 Analyst x1 330.22
2024 574.28 Est @ 18.31% 361.71
2025 648.28 Est @ 12.89% 378.04
2026 707.19 Est @ 9.09% 381.82
2027 752.67 Est @ 6.43% 376.24
2028 787.06 Est @ 4.57% 364.26
Present value of next 10 years cash flows $2,061.56
DB:BX2 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $787.06 × (1 + 0.23%) ÷ (8.01% – 0.23%)
$10,138.22
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $10,138.22 ÷ (1 + 8.01%)10
$4,692.05
DB:BX2 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,061.56 + $4,692.05
$6,753.62
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $6,753.62 / 15.67
$431.11
DB:BX2 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:BX2 represents 0.85977x of NasdaqCM:BTAI
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.85977x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 431.11 x 0.85977
€370.65
Value per share (EUR) From above. €370.65
Current discount Discount to share price of €8.36
= -1 x (€8.36 - €370.65) / €370.65
97.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BioXcel Therapeutics is available for.
Intrinsic value
>50%
Share price is €8.36 vs Future cash flow value of €370.65
Current Discount Checks
For BioXcel Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BioXcel Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • BioXcel Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioXcel Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioXcel Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BX2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.32
NasdaqCM:BTAI Share Price ** NasdaqCM (2019-04-18) in USD $9.72
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioXcel Therapeutics.

DB:BX2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:BTAI Share Price ÷ EPS (both in USD)

= 9.72 ÷ -1.32

-7.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioXcel Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • BioXcel Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does BioXcel Therapeutics's expected growth come at a high price?
Raw Data
DB:BX2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.35x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
53.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioXcel Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioXcel Therapeutics's assets?
Raw Data
DB:BX2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.48
NasdaqCM:BTAI Share Price * NasdaqCM (2019-04-18) in USD $9.72
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:BX2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:BTAI Share Price ÷ Book Value per Share (both in USD)

= 9.72 ÷ 2.48

3.91x

* Primary Listing of BioXcel Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioXcel Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess BioXcel Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BioXcel Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BioXcel Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
53.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioXcel Therapeutics expected to grow at an attractive rate?
  • BioXcel Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • BioXcel Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare BioXcel Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:BX2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BX2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 53.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BX2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BX2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 779 490 402 2
2022-12-31 332 78 110 2
2021-12-31 30 -86 -98 2
2020-12-31 0 -87 -85 3
2019-12-31 0 -45 -36 3
DB:BX2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -14 -19
2018-09-30 -10 -15
2018-06-30 -7 -11
2018-03-31 -3 -8
2017-12-31 -2 -5
2016-12-31 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioXcel Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if BioXcel Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BX2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from BioXcel Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BX2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 13.36 27.65 -0.94 2.00
2022-12-31 3.73 10.19 -2.73 2.00
2021-12-31 -3.08 -2.15 -4.33 3.00
2020-12-31 -3.37 -2.40 -4.83 4.00
2019-12-31 -2.22 -2.21 -2.24 2.00
DB:BX2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.32
2018-09-30 -1.11
2018-06-30 -0.92
2018-03-31 -0.81
2017-12-31 -0.47
2016-12-31 -0.22

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioXcel Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess BioXcel Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioXcel Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BioXcel Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioXcel Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioXcel Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare BioXcel Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioXcel Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BioXcel Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioXcel Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BX2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -19.27 5.40 14.56
2018-09-30 -14.72 5.21 9.97
2018-06-30 -10.75 4.21 6.76
2018-03-31 -8.29 2.99 5.31
2017-12-31 -4.54 1.85 2.69
2016-12-31 -2.12 0.72 1.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioXcel Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BioXcel Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BioXcel Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioXcel Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioXcel Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BioXcel Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioXcel Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioXcel Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioXcel Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioXcel Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BioXcel Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioXcel Therapeutics Company Filings, last reported 3 months ago.

DB:BX2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 38.89 0.00 42.57
2018-09-30 45.82 0.00 47.12
2018-06-30 49.82 0.00 50.35
2018-03-31 52.11 0.00 55.47
2017-12-31 -0.98 0.88 0.89
2016-12-31 -0.32 0.00
  • BioXcel Therapeutics has no debt.
  • BioXcel Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BioXcel Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • BioXcel Therapeutics has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 96.7% each year.
X
Financial health checks
We assess BioXcel Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioXcel Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BioXcel Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioXcel Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of BioXcel Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioXcel Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioXcel Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BX2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BX2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioXcel Therapeutics has not reported any payouts.
  • Unable to verify if BioXcel Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioXcel Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioXcel Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of BioXcel Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess BioXcel Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioXcel Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioXcel Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BioXcel Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Vimal Mehta
COMPENSATION $701,609
AGE 57
TENURE AS CEO 1.9 years
CEO Bio

Dr. Vimal D. Mehta, Ph.D., is Co-founder of BioXcel Corporation and serves as its Chairman and Chief Executive Officer. He has been Chief Executive Officer, President and Secretary of BioXcel Therapeutics, Inc. since May 2017 and has been its Director since April 2017. Dr. Mehta served as Senior Vice President of Global Business Development at Galapagos Biotech Ltd. Dr. Mehta joined Galapagos Biotech Ltd. in 2002. He was formerly a senior business development manager at CuraGen Corporation, which he joined in 1996. Dr. Mehta has had a significant scientific and business career spanning over 15 years, with a successful background in establishing partnerships with pharmaceutical and biotechnology leaders in the USA, Europe and Japan. Dr. Mehta is a business development professional with an illustrious scientific and business career spanning 20 years. From 1990 to 1996, Dr. Mehta was resident at the University of Texas Southwestern Medical Center at Dallas, initially as a postdoctoral fellow and later as an assistant professor. Dr. Mehta holds a Ph.D. in Chemistry from the University of Delhi, India and completed a Post-Doctoral Fellowship in Chemistry at the University of Montpellier, France.

CEO Compensation
  • Vimal's compensation has increased whilst company is loss making.
  • Vimal's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BioXcel Therapeutics management team in years:

1.2
Average Tenure
57
Average Age
  • The average tenure for the BioXcel Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Vimal Mehta

TITLE
Founder
COMPENSATION
$702K
AGE
57
TENURE
1.9 yrs

Frank Yocca

TITLE
Chief Scientific Officer
COMPENSATION
$654K
AGE
62
TENURE
1.8 yrs

Vince O'Neill

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$663K
AGE
49
TENURE
1.8 yrs

Rich Steinhart

TITLE
Chief Financial Officer
COMPENSATION
$447K
AGE
61
TENURE
1.5 yrs

Chids Mahadevan

TITLE
VP of Finance & Chief Accounting Officer
AGE
46

Cedric Burg

TITLE
VP and Head of Global Clinical Operations & Project Management
TENURE
0.8 yrs

David Hanley

TITLE
Head of Global Pharmaceutical Development and Operations & VP
TENURE
0.6 yrs

Chetan Lathia

TITLE
Senior VP and Head of Translational Medicine
TENURE
0.6 yrs

Robert Risinger

TITLE
Vice President of Clinical Development
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the BioXcel Therapeutics board of directors in years:

1.2
Average Tenure
56
Average Age
  • The average tenure for the BioXcel Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Peter Mueller

TITLE
Chairman of the Board of Directors
COMPENSATION
$337K
AGE
61
TENURE
1.7 yrs

Vimal Mehta

TITLE
Founder
COMPENSATION
$702K
AGE
57
TENURE
2 yrs

Sandeep Laumas

TITLE
Director
COMPENSATION
$315K
AGE
49
TENURE
1.6 yrs

Nandu Nandabalan

TITLE
Director
AGE
55
TENURE
1.9 yrs

Steve Paul

TITLE
Member of Advisory Board
AGE
67

Sheila Gujrathi

TITLE
Member of Advisory Board
AGE
48

Stephen Marder

TITLE
Member of Clinical Advisory Board
TENURE
0.8 yrs

George Grossberg

TITLE
Member of Clinical Advisory Board
TENURE
0.8 yrs

Alan Breier

TITLE
Member of Clinical Advisory Board
TENURE
0.8 yrs

Sheldon Preskorn

TITLE
Member of Clinical Advisory Board
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Dec 18 Buy Vimal Mehta Individual 14. Dec 18 14. Dec 18 2,000 €3.98 €7,761
07. Dec 18 Buy Peter Mueller Individual 06. Dec 18 07. Dec 18 8,795 €4.40 €38,645
06. Dec 18 Buy Peter Mueller Individual 04. Dec 18 04. Dec 18 4,007 €4.54 €18,093
06. Dec 18 Buy Frank Yocca Individual 03. Dec 18 04. Dec 18 900 €4.61 €4,132
04. Dec 18 Buy Vimal Mehta Individual 03. Dec 18 04. Dec 18 2,000 €4.58 €9,058
04. Dec 18 Buy Richard Steinhart Individual 03. Dec 18 03. Dec 18 500 €4.58 €2,290
30. Nov 18 Buy Krishnan Nandabalan Individual 29. Nov 18 29. Nov 18 1,000 €4.32 €4,319
30. Nov 18 Buy Vimal Mehta Individual 30. Nov 18 30. Nov 18 1,000 €4.59 €4,508
30. Nov 18 Buy Frank Yocca Individual 29. Nov 18 30. Nov 18 950 €4.59 €4,284
30. Nov 18 Buy Richard Steinhart Individual 29. Nov 18 30. Nov 18 1,000 €4.42 €4,416
14. Sep 18 Buy DNCA Finance Company 27. Aug 18 27. Aug 18 94,801 €7.07 €670,110
X
Management checks
We assess BioXcel Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioXcel Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA, Nektar Therapeutics, and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.

Details
Name: BioXcel Therapeutics, Inc.
BX2
Exchange: DB
Founded: 2017
$135,460,811
15,665,802
Website: http://www.bioxceltherapeutics.com
Address: BioXcel Therapeutics, Inc.
555 Long Wharf Drive,
5th Floor,
New Haven,
Connecticut, 06511,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM BTAI Common Stock Nasdaq Capital Market US USD 08. Mar 2018
DB BX2 Common Stock Deutsche Boerse AG DE EUR 08. Mar 2018
Number of employees
Current staff
Staff numbers
18
BioXcel Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:48
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/03/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.